WallStSmart

Merck & Company Inc (MRK)vsOncology Institute Inc (TOI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 12097% more annual revenue ($66.57B vs $545.76M). MRK leads profitability with a 4.8% profit margin vs -8.0%. TOI earns a higher WallStSmart Score of 45/100 (D+).

MRK

Avoid

34

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

TOI

Hold

45

out of 100

Grade: D+

Growth: 8.0Profit: 2.0Value: 6.0Quality: 5.5
Piotroski: 5/9Altman Z: 0.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-84.6%)

Margin of Safety

-84.6%

Fair Value

$82.62

Current Price

$149.54

$66.92 premium

UndervaluedFair: $82.62Overvalued
TOIUndervalued (+22.9%)

Margin of Safety

+22.9%

Fair Value

$3.40

Current Price

$5.13

$1.73 discount

UndervaluedFair: $3.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$335.46B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

TOI2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
41.2%10/10

Revenue surging 41.2% year-over-year

Debt/EquityHealth
-6.4410/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.8x4/10

Trading at 8.8x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

TOI4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$512.91M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-652.0%2/10

ROE of -652.0% — below average capital efficiency

Free Cash FlowQuality
$-3.26M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : TOI

The strongest argument for TOI centers on Revenue Growth, Debt/Equity. Revenue growth of 41.2% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 108.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : TOI

The primary concerns for TOI are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while TOI is a hypergrowth play — different risk/reward profiles.

TOI carries more volatility with a beta of 0.42 — expect wider price swings.

TOI is growing revenue faster at 41.2% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

TOI scores higher overall (45/100 vs 34/100) and 41.2% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Oncology Institute Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Oncology Institute Inc (ticker: TOI) is a leading healthcare organization focused on revolutionizing cancer care through its extensive network of specialized clinics and innovative treatment methodologies. By harnessing advanced technologies and personalized care strategies, the company aims to significantly improve patient outcomes while emphasizing clinical trials and partnerships with premier research institutions. Positioned to capitalize on the growing demand for advanced cancer therapies, TOI benefits from a solid pipeline and a wealth of oncology expertise, presenting a compelling investment opportunity within the dynamic healthcare landscape.

Visit Website →

Want to dig deeper into these stocks?